



ABLYNX WINS AWARD FOR 'MOST SUCCESSFUL EARLY PHASE TRIAL'

GHENT, Belgium, 23 October 2009 - Ablynx [*Euronext Brussels: ABLX*] is pleased to announce it has been awarded 'Most Successful Early Phase Trial' at the 2009 Good Clinical Practice Journal's (GCPj) Clinical Research Excellence Awards in London. The GCPj's Awards recognise excellence in clinical research and development.

Commenting on the award, Chief Medical Officer Josi Holz said: "It is a great honour to receive this prestigious award. We are pleased that our lead programme, a novel anti-thrombotic, ALX-0081 entered a Phase II study in patients undergoing percutaneous coronary intervention (PCI) last month. The award recognises our innovative Phase I clinical trial design and the acceleration of this programme through the use of biomarkers and PK/PD modelling to establish biological effective dosing in patients. We have achieved the rapid progress with ALX-0081 thanks to a dedicated Ablynx team and our collaborators at the OLVZ in Aalst and PRA International."

-ends-

About ALX-0681 and ALX-0081

ALX-0681 and ALX-0081 are novel "first-in-class" therapeutic Nanobodies[®] targeting von Willebrand factor ("vWF"), a protein found in the blood that acts at a very early stage in the coagulation cascade, namely platelet adhesion, in contrast to currently available anti-platelet drugs which act only in the late stage of platelet aggregation. ALX-0081 is administered intravenously while ALX-0681 is administered subcutaneously. ALX-0081 is a bivalent Nanobody[®] with a molecular weight of 28,000 daltons, designed to selectively prevent unwanted thrombus formation in vessels under high shear conditions without interfering with desirable haemostasis and, as such, to minimize bleeding complications.

About Ablynx [*Euronext Brussels: ABLX*] - <http://www.ablynx.com>

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies[®], a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 220 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

Ablynx is developing a portfolio of Nanobody[®]-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Nanobodies[®] have been generated against more than 150 different disease targets. Efficacy data have been obtained in over 26 *in vivo* models for Nanobodies[®] against a range of different targets.

Ablynx has an extensive patent position in the field of Nanobodies[®] for healthcare applications. It has exclusive and worldwide rights to more than 50 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies[®].

Ablynx has ongoing research collaborations and significant partnerships with several major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Wyeth Pharmaceuticals. Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies[®] through these collaborations as well as through its own internal discovery programmes.

The Company's lead programme, ALX-0081, an intravenously administered novel anti-thrombotic has entered Phase II in patients undergoing percutaneous coronary intervention (PCI). ALX-0681, a subcutaneous formulation of the novel anti-thrombotic Nanobodies[®] that also selectively targets von Willebrand factor (vWF) has concluded Phase I. Ablynx has progressed ALX-0141, an anti-RANKL Nanobody[®] for bone disorders into preclinical development and aims to initiate a Phase I study before the end of 2009. ALX-0061, an anti IL6R Nanobody[®] is in preclinical development for the treatment of autoimmune and inflammatory diseases. In addition, in December 2008, Ablynx's partner Wyeth Pharmaceuticals entered a Phase I study with an anti-TNF-alpha Nanobody[®] and a Phase II study was initiated in September 2009.

Nanobody[®] is a registered trademark of Ablynx NV.

For more information, please contact:

For international media enquiries:

College Hill Life Sciences

Sue Charles, Justine Lamond,

Dr John McIntyre

t: +44 (0)20 7866 7857

e: ablynx@collegehill.com

Ablynx:

Dr Edwin Moses

Chairman and CEO

t: +32 (0)9 262 00 07

m: +44 (0)7771 954 193 /

+32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Eva-Lotta Allan

Chief Business Officer

t: +32 (0)9 262 00 75

m: +32 (0)475 78 36 21 /

+44 (0)7990 570 900

e: eva-lotta.allan@ablynx.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.